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Abstract
Background: Drug combination that consists of distinctive agents is an attractive strategy to combat complex
diseases and has been widely used clinically with improved therapeutic effects. However, the identification of
efficacious drug combinations remains a non-trivial and challenging task due to the huge number of possible
combinations among the candidate drugs. As an important factor, the molecular context in which drugs exert their
functions can provide crucial insights into the mechanism underlying drug combinations.
Results: In this work, we present a network biology approach to investigate drug combinations and their target
proteins in the context of genetic interaction networks and the related human pathways, in order to better
understand the underlying rules of effective drug combinations. Our results indicate that combinatorial drugs tend
to have a smaller effect radius in the genetic interaction networks, which is an important parameter to describe
the therapeutic effect of a drug combination from the network perspective. We also find that drug combinations
are more likely to modulate functionally related pathways.
Conclusions: This study confirms that the molecular networks where drug combinations exert their functions can
indeed provide important insights into the underlying rules of effective drug combinations. We hope that our
findings can help shortcut the expedition of the future discovery of novel drug combinations.
Background
Drug combination refers to the combination of different
agents that can achieve better efficacy but less side effects
compared to any of its component drugs. Generally, drug
combinations are composed of compounds that are single
effective drugs. Recently, drug combination is becoming a
promising and popular strategy in the clinic, especially in
treating complex diseases such as cancer [1-3]. For exam-
ple, DuoDote is the combination of Atropine and Prali-
doxime, which is an approved combinatorial drug used to
treat patients with antidote for organophosphorous [4].
Chan et al. [5] designed a combinatorial drug, namely Tri-
Luma (containing fluocinolone acetonide, hydroquinone
and tretinoin), for combating melasma (dark skin patches)
of the face based on the efficacy and safety experiments.
Agrawal et al. [6] found two effective combinatorial regi-
mens to treat Huntington disease based on screening in
Drosophila.
Despite these efforts that have been made to discover
new drug combinations in the past few decades, a large
portion of the effective combinatorial drugs clinically
used were discovered through experiences that generally
require labor-intensive and time-consuming “brute force”
screening of all possible combinations between the
approved individual drugs. When two drugs are adminis-
tered together, one drug may promote or suppress the
effect of the other. For instance, cyclosporine increases
the effect of sirolimus, while bupropion decreases the
effect of cyclosporine. As a result, the combination of
two drugs may have a totally new effect that is different
and unexpected from either individual drug [7,8].
Furthermore, the number of possible combinations will
increase exponentially with the increasing availability of
single drugs. For example, in the case of four drugs, there
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extremely large considering the fact that there are thou-
sands of approved drugs. Due to the huge search space of
possible combinations between known drugs, the identifi-
cation of optimal and effective drug combinations is a
challenging task.
Recently, a number of computational methods have
been proposed to predict new drug combinations prior
to combination synthesis and practical test in the lab. For
example, Calzolari et al. [9] devised an efficient search
algorithm originated from information theory to optimize
drug combinations based on the sequential decoding
algorithms. Geva-Zatorsky et al. [10] found that the pro-
tein dynamics in response to drug combination can be
accurately described by a linear superposition of the
dynamics under the corresponding individual drugs. In
our recent work [11], we proposed a statistical model to
predict new combinations based on a “drug cocktail” net-
work constructed from effective drug combinations. We
found that the effective combinations can be predicted
based on the therapeutic effects of drugs and their inter-
action partners. Thanks to the completion of human gen-
ome sequencing projects, extensive systems biology
efforts have been made to discover new combinations,
especially from the network biology perspective in the
past few years [11-14], from which the drug combina-
tions can be identified based on the subnetworks or path-
ways perturbed by drugs [15,16]. Most recently, Zhao
et al. [17] proposed a novel approach to predict drug
combinations by integrating molecular and pharmlogical
data, yielding promising results.
In general, one drug acquires the desired therapeutic
effects by affecting the biological systems through the
molecular pathways or biological processes pertinent to its
target protein(s) [18]. For drug combinations, different
component compounds may target different biochemical
pathways to overcome the redundant processes dysregu-
lated due to diseases. Therefore, the network circuits
within which a drug functions should provide useful
insights into the action mechanism underlying this drug,
and thus help to understand the rules that underlie drug
combinations. In this work, we explored drug combina-
tions in the molecular space through the protein targets
modulated by drugs. In particular, the proteins targeted by
drugs were investigated in the context of genetic interac-
tion map and pathway circuits. The genetic interactions
were considered here because they are found important to
drug actions [19] and causality of diseases [20]. Our results
demonstrate that the proteins targeted by different com-
pounds from one combination tend to have shorter dis-
tance within genetic interaction networks when compared
with those of random combinations. Furthermore, drug
combinations are found to be more likely to target the
interacting pathways. We believe that the findings in this
study can help to better understand the rules underlying
drug combinations and are useful for predicting novel
combinatorial drugs in the future.
Results and discussion
To explore the effective drug combinations, a drug cock-
tail network was constructed following the same proce-
dures as described in our previous work [11], where each
node represented a drug while an edge was connected
between the two drugs if they can be combined. In addi-
tion, we compared the effective combinations against the
random combinations, which were generated by randomly
shuffling the edges in the drug cocktail network while pre-
serving the node degrees.
Drug combinations tend to have shorter effect radius
We firstly investigated the effect radius of both drug
combinations and random combinations. Figure 1 shows
the percentage of drug combinations with respect to
their effect radius. Here, the genetic interactions between
genes were considered because they are important for
understanding drug combinations [19]. We can see that
most drug combinations (62%) have short radius less
than 3. Drug combinations have significantly shorter
effect radius (p-value = 0.002 by the Wilcoxon test) com-
pared with the random combinations, which implies that
drug combinations may achieve their effects by modulat-
ing genetic interactions.
Furthermore, we investigated the therapeutic categories
of the drugs invovled in combinations that have smaller
effect radius (<=3) and those have larger effect radius (>3)
(Figure 2). We can see that these two groups of drug com-
binations have some differences with respect to their ther-
apeutic effects. For example, the drugs indicated for
cardiovascular diseases and nervous diseases are the first
two largest categories of drug combinations that have
smaller effect radius, while the antineoplastic and immu-
nomodulating agents are the largest group for drug combi-
nations that have larger effect radius.
Drug combinations tend to target the interacting and
cross-talking pathways
Using the target protein information, each drug was asso-
ciated with the pathways in which its target proteins can
be found. By grouping the relationships between the two
pathways targeted by different agents of a combinatorial
drug into four categories, i.e. interacting, cross-talking,
identical, and parallel (see Methods), we found that drug
combinations tend to significantly target the cross-talking
(p-value 1.6e-45 by the Wilcoxon rank-sum test) and
interacting pathways (p-value 4.3e-31 by the Wilcoxon
rank-sum test) compared with the random combinations.
Figure 3 shows the distribution of drug combinations
according to the propotions of different pathway pairs
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pathways targeted by drug combinations, we can see that
most drugs are combined through the modulation of
functionally related pathways, offering insightful clues to
the identification of new drug combinations in the future.
The dominant interacting pathways targeted by drug
combinations also imply that genetic interactions may
play important roles in drug combinations, which was
confirmed recently [19].
Specifically, we investigated the types of drug combina-
tions that target interacting pathways. In the DCDB data-
base, the drug combinations are roughly grouped into
four categories: synergistic, additive, antagonistic and
potentiative (details can be found in the DCDB database).
Focusing on the drug combinations that target interact-
ing pathways (i.e. drug combinations that have interact-
ing pathways with the proportion larger than 0.4 in
Figure 3A), we found that for the drug combinations that
modulate interacting pathways, most are annotated as
synergistic combinations as shown in Figure 4. In other
words, drugs targeting distinctive but functionally related
pathways may lead to synergestic therapeutic effects if
they are used concurrently. We speculated that synergis-
tic drug combinations may achieve their effects through
Figure 1 The percentage of drug combinations with different effect radius.
Figure 2 The therapeutic categories of drugs involved in combinations with respect to their effect radius. (A) Effect radius less than or
equal to 3. (B) Effect radius larger than 3.
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pathways. In general, the more pathways a drug affects,
the more possible side effects it may introduce. The
interacting pathways targeted by drug combinations may
help to explain why synergistic drug combinations have
higher selectivity or less side effects compared with their
individual components [21].
Furthermore, we investigated the therapeutic effects of
drug combinations that target the interacting pathways.
Figure 5 shows the therapeutic categories of different
drug combinations. There are 194 drug combinations
that target interacting pathways, and most of the drugs
involved are related to diverse disease types, including
cardiovascular, neural and immune system related
Figure 3 The percentage of drug combinations with respect to the proportion of different types of pathway pairs targeted by the
combinations. (A) Cross-talking pathways. (B) Interacting pathways.
Figure 4 Distribution of different types of drug combinations that target the interacting pathways.
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do not target interacting pathways are indicated for car-
diovascular diseases. In addition, we checked the proteins
targeted by those drug combinations that tend to regulate
interacting pathways (Figure 6). We found that these
drug combinations modulate proteins with a broad range
of biological functions, in which the G-protein coupled
receptors (GPCRs) are predominantly involved. In sum-
mary, we found that the drugs involved in effective com-
binations that regulate interacting pathways are
significantly different from those that do not tend to tar-
get interacting pathways, and further the former modu-
lates proteins with a variety of biological functions.
Conclusions
Drug combination is a promising strategy for combating
complex disease, however, our understanding of mechan-
isms that underlie drug combinations is largely lacking at
present. In this work, we explored drug combinations in
the molecular space, especially in the context of genetic
interaction networks and the pathways in which the tar-
get proteins function. By comparing the effective drug
combinations and random combinations, we found that
drug combinations tend to target proteins that are close
in the genetic interaction networks. In addition, drugs
that tend to modulate functionally related pathways or
biological processes are likely to lead to synergistic inter-
actions if they are administered concurrently. From our
analysis, we conclude that the genetic interactions play
important roles in drug combinations and can help to




The drug combinations were retrieved from a newly
released Drug Combination Database (DCDB) [22],
which is a major resource for collecting effective drug
combinations from the literature. The target proteins and
therapeutic (represented as Anatomical Therapeutic Che-
mical (ATC) classification system) information associated
with the drugs were extracted from DrugBank [23]. In
particular, the non-specific target proteins were discarded
as described in [24]. Drug combinations that consist of
drugs without the ATC annotation or target information
were also discarded. Consequently, 444 effective drug
combinations were obtained, including 182 approved, 54
clinical and 208 preclinical combinations. Based on these
drug combinations, a drug cocktail network was con-
structed where each node represented a drug and an
edge was added for the two drugs that were involved in
the same combination. The random combinations were
generated by randomly shuffling the edges in the drug
cocktail network while preserving the degree for each
node. This procedure was repeated for 1,000 times.
Human genetic interactions were obtained from [25]
which were inferred by utilizing the radiation hybrid gen-
otyping data. Here, only the interactions with p-value less
than 1.0e-7 were considered. In addition, we obtained
234 pathways from the KEGG [26] database.
The effect radius of a combinatorial drug
Given the drug components in a combination and their
corresponding target proteins, the distance dis(i,j)
between the two drugs i and j is defined as the shortest
Figure 5 The therapeutic categories of drugs involved in combinations with respect to the proportion of their targeted interacting
pathways. (A) Proportion of the interacting pathways larger than 0.4. (B) Proportion less than or equal to 0.4.
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and j, where the distance between two proteins is calcu-
lated as the shortest path distance within the genetic
interaction network. Wherever the distance between any
two drugs is available, the effect radius of a combination






where R is the effect radius of one combinatorial drug, dis
(i,j) denotes the distance between drugs i and j, D is the set
of all possible combinations between the components of a
drug combination, and |D|i st h es i z eo fD, respectively.
The interaction between pathways and drug
combinations
For the two drugs in a combination, each can be asso-
ciated with pathways to which its target proteins belong,
and therefore two pathway sets are constructed for
these two drugs. Given a pair of pathways that are
respectively associated with these two drugs, we grouped
this pathway pair into one of the following four cate-
gories: identical, cross-talking, interacting, and parallel
and unrelated. The cross-talking pathways are those that
have at least one common gene, the interacting path-
ways have genetic interaction(s) between the two path-
ways, while the parallel and unrelated pathways consist
of two totally different pathways without any functional
relationships. For a given drug combination, we investi-
gated the proportion of the four types of pathway pairs
modulated by the combination.
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